831 results match your criteria Cancer biomarkers : section A of Disease markers[Journal]


Nomogram based on pre-treatment inflammatory biomarkers predicting survival in patients with head and neck soft tissue sarcoma.

Cancer Biomark 2020 Jul 3. Epub 2020 Jul 3.

Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Chengdu, Sichuan, China.

Background: Systemic inflammatory biomarkers reflect level of inflammatory response, which have been suggested as prognostic factors in cancer patients.

Objective: To estimate the prognostic value of inflammatory biomarkers in 149 patients with head and neck soft tissue sarcoma (HNSTS).

Methods: Pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), neutrophil-platelet score (NPS) and Aarhus Composite Biomarker Score (ACBS) were analyzed for association with overall survival (OS) and progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-201739DOI Listing

Serum interleukin-8 as a potential diagnostic biomarker in esophageal squamous cell carcinoma.

Cancer Biomark 2020 Jun 24. Epub 2020 Jun 24.

The Cancer Hospital of Shantou University Medical College, Guangdong, China.

Background: Esophageal squamous cell carcinoma (ESCC) has poor prognosis mainly due to the difficulty of making early diagnosis. Therefore, novel biomarkers are critically needed.

Objective: We aimed to investigate the diagnostic value of serum interleukin-8 (IL-8) in ESCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-201687DOI Listing

Screening and identification of key biomarkers in alimentary tract cancers: A bioinformatic analysis.

Cancer Biomark 2020 Jul 1. Epub 2020 Jul 1.

Center of Gastrointestinal disease, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.

Alimentary tract cancers (ATCs) are the most malignant cancers in the world. Numerous studies have revealed the tumorigenesis, diagnosis and treatment of ATCs, but many mechanisms remain to be explored. To identify the key genes of ATCs, microarray datasets of oesophageal cancer, gastric cancer and colorectal cancer were obtained from the Gene Expression Omnibus (GEO) database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-201580DOI Listing

Identification of let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.

Cancer Biomark 2020 Jun 28. Epub 2020 Jun 28.

Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

Background: Among patients diagnosed with non-muscle invasive bladder cancer (NMIBC), 30% to 70% experience recurrences within 6 to 12 years of diagnosis. The need to screen for these events every 3 to 6 months and ultimately annually by cystoscopy makes bladder cancer one of the most expensive malignancies to manage.

Objective: The of this study was to identify reproducible prognostic microRNAs in resected non-muscle invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype as potential biomarkers and molecular therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191322DOI Listing

Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.

Cancer Biomark 2020 Jul 3. Epub 2020 Jul 3.

Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy.

Background: The time-related variability of HCC biomarkers has not been investigated so far.

Objective: To assess the changes of alpha-fetoprotein (AFP) and protein induced by vitamin-K absence/antagonist-II (PIVKA-II) in patients with HCC (HCC+) as compared to patients without HCC (HCC-).

Methods: AFP and PIVKA-II were measured by a single laboratory using an automated chemiluminescent-enzyme-immunoassay (Fujirebio Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190118DOI Listing

CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.

Authors:
Jun Wu

Cancer Biomark 2020 Jun 19. Epub 2020 Jun 19.

Background: The CKLF-like MARVEL transmembrane domain-containing family (CMTM) is the protein product of at least one splice variant of each gene contained a Marvel (MAL and related proteins for vesicle trafficking and membrane link) domain, involved in a variety of cellular processes and the pathogenesis of diseases, including tumorigenesis. However, the diverse expression patterns and prognostic values of eight CMTMs have yet to be elucidated.

Objective: We analyzed the expressions and impacts on survival of different CMTM factors in BC patients to determine their potential diagnosis and prognosis values in BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191226DOI Listing

Application of proximity ligation assays to identify potential plasma biomarkers in oral cavity cancer patients: A case control study.

Cancer Biomark 2020 Jun 12. Epub 2020 Jun 12.

Department of Otolaryngology, Taichung Veterans General Hospital, Taichung, Taiwan.

Background: Practical cancer biomarkers for oral cavity cancer are currently in limited use.

Objective: We aimed to investigate the differences in soluble E-cadherin between patients with oral cavity cancer and matched healthy participants via Proximity Ligation Assay (PLA).

Methods: Samples were taken from both patients diagnosed with oral cavity cancer, as well as non-cancerous participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191195DOI Listing

miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia.

Cancer Biomark 2020 Jun 19. Epub 2020 Jun 19.

Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Background: MicroRNA (miRNA) expression has been implicated in leukaemia. In recent years, miRNAs have been under investigation for their potential as non-invasive biomarkers in acute promyelocytic leukaemia (APL). We investigated whether miR-638 in circulating leukaemia cells is a non-invasive biomarker in diagnosis, assessment of the treatment response and minimal residual disease (MRD) surveillance of APL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190899DOI Listing

MiR-204-5p/TFAP2A feedback loop positively regulates the proliferation, migration, invasion and EMT process in cervical cancer.

Cancer Biomark 2020 May 21. Epub 2020 May 21.

MicroRNAs (MiRNAs) have been clarified as crucial regulators of the pathological processes in various carcinomas in the past years. Interestingly, existing evidence has manifested that microRNA-204-5p (miR-204-5p) is engaged in the initiation and progression of multiple carcinomas. However, the potential of miR-204-5p in cervical cancer remains to be disentombed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191064DOI Listing

Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.

Cancer Biomark 2020 May 9. Epub 2020 May 9.

Hematology Unit, Clinical Pathology Department, Mansoura University Oncology Center, Mansoura University, Mansoura, Egypt.

Background: This study aimed to assess the significance of combined expression of interleukin-2 receptor (CD25) and the interleukin-3 receptor (CD123) in acute myeloid leukemia (AML) patients.

Methods: The expression of CD25 and CD123 on blast cells in bone marrow samples were identified by flowcytometry in 94 patients (⩽ 60 years old) with de novo acute myeloid leukemia (AML) treated at the Mansoura University Oncology Center (MUOC).

Results: Of the 94 samples at diagnosis there were 17 (18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-201519DOI Listing
May 2020
1.186 Impact Factor

High expression of IGF2-derived intronic miR-483 predicts outcome in hepatoblastoma.

Cancer Biomark 2020 Apr 30. Epub 2020 Apr 30.

Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.

Background: The role of microRNAs (miRs) as biomarkers to predict outcome in hepatoblastoma (HB), the most common malignant liver tumor in childhood, has still to be determined. Recently, the so-called four-miR signature has been described to efficiently stratify HB patients according to their prognosis.

Objective: We examined the recently described four-miR signature for its clinical relevance in an independent validation cohort of HB patients and tried to optimize its predictive value by analyzing four additional miRs involved in HB biology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191390DOI Listing

Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.

Cancer Biomark 2020 ;28(2):255-268

"CI Parhon" National Institute of Endocrinology, Bucharest, Romania.

Purpose: DNA methylation plays an important role in thyroid oncogenesis. The aim of this study was to investigate the connection between global and local DNA methylation status and to establish the levels of important DNA methylation regulators (TET family and DNMT1) in thyroid tumours: follicular adenoma-FA, papillary thyroid carcinoma-PTC (classic papillary thyroid carcinoma-cPTC and papillary thyroid carcinoma follicular variant fvPTC).

Methods: Global DNA methylation profile in thyroid tumours tissue (41 paired samples) was assessed by 5-methylcytosine and 5-hydroxymethylcytosine levels evaluation (ELISA), along with TETs and DNMT1 genes expression quantification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190871DOI Listing
January 2020

Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.

Cancer Biomark 2020 Apr 30. Epub 2020 Apr 30.

Division of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Background: Effective prognostic biomarkers and powerful target-therapeutic drugs are needed for improving the treatment of Hepatocellular carcinoma (HCC).

Objective: This study aimed to evaluate the expression of FOXM1 and Aurora-A and their prognostic value in HCC.

Methods: We determined the differentially expressed genes signature in HCC using the Gene Set Enrichment Analysis (GSEA), and then evaluated the expression of FOXM1 and Aurora-A in TCGA and KMUH cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190507DOI Listing

Molecular characterisation in tongue squamous cell carcinoma reveals key variants potentially linked to clinical outcomes.

Cancer Biomark 2020 ;28(2):213-220

Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.

Background: Oral tongue squamous cell carcinoma (OTSCC) is a highly aggressive malignancy characterized by frequent recurrence, poor survival with relatively few therapeutic options due to the late diagnosis in many cases.

Objectives: Understanding the molecular pathways underlying OTSCC tumourigenesis and the discovery of diagnostic and/or prognostic biomarkers.

Methods: We performed high-throughput mutational analysis of 44 OTSCC formalin-fixed paraffin-embedded (FFPE) cases using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190897DOI Listing
January 2020
1.186 Impact Factor

Identification of key long non-coding RNAs in gastric adenocarcinoma.

Cancer Biomark 2020 ;27(4):541-553

Background: Gastric cancer is the third leading cause of cancer-related deaths worldwide.

Objective: The present study aims to identify key long non-coding RNAs (lncRNAs) and their potential roles in the pathogenesis of gastric adenocarcinoma.

Methods: The lncRNA and mRNA expression profile between gastric adenocarcinoma and adjacent non-tumor tissues were obtained from The Cancer Genome Atlas (TCGA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-192389DOI Listing
January 2020

Integrative analyses of molecular pathways and key candidate biomarkers associated with colorectal cancer.

Authors:
Dilek Pirim

Cancer Biomark 2020 ;27(4):555-568

Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths and mining the molecular factors underlying CRC pathogenesis is imperative for alleviating the disease burden.

Objective: To highlight key molecular pathways, prioritize hub genes and their regulators related to CRC.

Methods: Data sets of TCGA-COAD and GTEx were used to identify differentially expressed genes (DEGs) and their functional enrichments in pathways and biological processes were analyzed using bioinformatics tools. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191263DOI Listing
January 2020

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia.

Cancer Biomark 2020 ;28(2):151-158

Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.

Background: The interest in plasma biomarkers has increased recently. Plasma exosome-derived microRNA-532 is aberrantly expressed in a variety of human cancers and has the prognostic value in many solid tumors. However, the prognostic impact of the expression value on AML remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191164DOI Listing
January 2020

Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.

Cancer Biomark 2020 ;28(2):159-167

Division of Molecular Epidemiology, German Cancer Research Center, Heidelberg, Germany.

Background: Minimal invasive blood-based molecular markers are evaluated as promising biomarkers in malignant diseases these days.

Objective: In this pilot study, we investigated the potential of cell-free DNA (cfDNA) concentration and cell-free DNA Integrity (cfDI) as blood-based diagnostic markers for ovarian cancer patients in a retrospective study cohort.

Methods: cfDNA concentration and cfDI were determined in the plasma of 37 ovarian cancer patients and 28 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative real-time PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191018DOI Listing
January 2020

Discovery of potential serum and urine-based microRNA as minimally-invasive biomarkers for breast and gynecological cancer.

Cancer Biomark 2020 ;27(2):225-242

Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, Freiburg, Germany.

Background: Deregulated microRNAs (miRNAs) in breast and gynecological cancer might contribute to improve early detection of female malignancies.

Objective: Specification of miRNA types in serum and urine as minimally-invasive biomarkers for breast (BC), endometrial (EC) and ovarian cancer (OC).

Methods: In a discovery phase, serum and urine samples from 17 BC, five EC and five OC patients vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190575DOI Listing
January 2020

Co-expression network analysis identified atypical chemokine receptor 1 (ACKR1) association with lymph node metastasis and prognosis in cervical cancer.

Cancer Biomark 2020 ;27(2):213-223

Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Cervical cancer (CC) is one kind of female cancer. With the development of bioinformatics, targeted specific biomarkers therapy has become much more valuable. GSE26511 was obtained from gene expression omnibus (GEO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190533DOI Listing
January 2020

Identifying prognostic biomarkers of non-small cell lung cancer by transcriptome analysis.

Cancer Biomark 2020 ;27(2):243-250

Background: Prognostic biomarkers are promising targets for cancer prevention and treatment.

Objective: We try to filtrate survival-related genes for non-small cell lung cancer (NSCLC) via transcriptome analysis.

Methods: Transcriptome data and clinical information of Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), mainly subtypes of NSCLC, were obtained from The Cancer Genome Atlas (TCGA) program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190222DOI Listing
January 2020

Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.

Cancer Biomark 2020 ;27(3):407-421

Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA.

Background: The majority of ovarian cancer cases are diagnosed at an advanced stage with poor prognosis. This study evaluates autoantibodies against tumor antigens to identify candidate biomarkers for early detection of ovarian cancer in women at increased risk.

Objective: To assess the immunoreactivity of paraneoplastic antigens and tumor associated antigens with high-grade serous ovarian cancer (HGSOC) samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190988DOI Listing
January 2020

Novel somatic alterations underlie Chinese papillary thyroid carcinoma.

Cancer Biomark 2020 ;27(4):445-460

Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

To characterize the somatic alterations of papillary thyroid carcinomas (PTC) in Chinese patients, we performed the next-generation-sequencing (NGS) study of the tumor-normal pairs of DNA and RNA samples extracted from 16 Chinese PTC patients. The whole genome sequencing (WGS) and transcriptome sequencing (RNA-seq) were conducted for 6 patients who were either current or former smokers and the whole exome sequencing (WES) and RNA-seq were conducted for another 10 patients who were never smokers. The NGS data were analyzed to identify somatic alteration events that may underlie PTC in Chinese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191200DOI Listing
January 2020

Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing.

Cancer Biomark 2020 ;27(3):389-397

Department of Pancreatic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China.

Objectives: Pancreatic cancer is one of the most lethal malignancies worldwide. Pancreatic adenosquamous carcinoma (PASC) is a rare histological type of pancreatic carcinoma with a poor prognosis. The median survival time after diagnosis is less than one year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190236DOI Listing
January 2020

Circulating Epstein-Barr virus microRNA profile reveals novel biomarker for nasopharyngeal carcinoma diagnosis.

Cancer Biomark 2020 ;27(3):365-375

Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.

Nasopharyngeal carcinoma (NPC), a tumor quite prevalent in Asia, is closely associated with Epstein-Barr virus (EBV) infection status. Many NPC patients are not able to be treated in time when being diagnosed at an advanced stage. EBV-encoded microRNAs are reliable sources of biomarkers for NPC diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190160DOI Listing
January 2020

Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma.

Cancer Biomark 2020 ;27(2):265-275

Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Background: Tumor-infiltrating immune cells are indispensable to the progression and prognosis of clear cell renal cell carcinoma (ccRCC).

Objective: The aim of this study was to explore the clinical implications of immune cell infiltrates in ccRCC.

Methods: The Cancer Genome Atlas (TCGA) database (N= 515) and E-MTAB-1980 cohort of patients (N= 101) were adopted to estimate the prognostic value of immune cell infiltration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-191017DOI Listing
January 2020

ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.

Cancer Biomark 2020 ;27(2):251-264

General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Background: The recognition of high-risk colon cancer patients prone to chemoresistant and recurrent disease is a challenge.

Objectives: We aimed to assess the immunohistochemical expression of ERCC1, PARP-1, and AQP1 in 60 cases of stage II and III colon cancer who underwent curative resection and adjuvant chemotherapy. Their predictive role of tumor progression and disease-free survival (DFS) was analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190994DOI Listing
January 2020
1.186 Impact Factor

MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer.

Cancer Biomark 2020 ;27(4):423-432

Department of Vascular and Thyroid and Breast Surgery, Shanxian Central Hospital, Heze, Shandong, China.

Background: MicroRNAs (miRNAs) have been reported to serve as potential biomarkers in various cancer and play important roles in tumor progression.

Objective: The aim of this study was to investigate the prognostic significance and functional role of miR-383-5p in breast cancer.

Methods: The expression levels of miR-383-5p in breast cancer tissues and cell lines were measured using quantitative real-time PCR analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190704DOI Listing
January 2020

Evaluation of a panel of tumor-associated antigens in breast cancer.

Cancer Biomark 2020 ;27(2):207-211

Genomics Sciences Program, Autonomous University of Mexico City, CDMX, Mexico.

Background: Recent studies indicate that serum from cancer patients contains auto-antibodies against oncoproteins so called tumor-associated antigens (TAAs), which represent promising diagnostic and prognostic biomarkers.

Objectives: In this study we searched for breast cancer-associated auto-antibodies against individual TAAs. Also we evaluated if a panel of multiple TTAs would improve the detection of auto-antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190708DOI Listing
January 2020

Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.

Cancer Biomark 2020 ;27(3):313-323

Medical College of Soochow University, Soochow, China.

Background And Objective: Chemotherapy remains the basis of the treatment of lung cancer, and screening biomarkers with predictive value for chemotherapy is of great interest. The present study focused on status of genes methylation in NSCLC patients receiving pemetrexed- or gemcitabine-based chemotherapy.

Patients And Methods: Promoter methylation of Ras association domain family (RASSF1A) and short stature homeobox 2 (SHOX2) was examined in bronchoalveolar lavage (BAL) from 117 NSCLC patients treated with chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190258DOI Listing
January 2020

Screening key lncRNAs with diagnostic and prognostic value for head and neck squamous cell carcinoma based on machine learning and mRNA-lncRNA co-expression network analysis.

Cancer Biomark 2020 ;27(2):195-206

Department of Head and Neck Surgery, Hunan Cancer Hospital and the Affliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan, China.

Background: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common type of cancer around the world. The aim of this study was to seek the long non-coding RNAs (lncRNAs) acting as diagnostic and prognostic biomarker of HNSCC.

Methods: Base on TCGA dataset, the differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) were identified between HNSCC and normal tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190694DOI Listing
January 2020

Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer.

Cancer Biomark 2020 ;27(1):113-120

Department of Human Anatomy, Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.

Background: Increasing evidence have shown that miRNAs play an important role in the development and progression of non-small cell lung cancer (NSCLC).

Objective: In this study, we aimed to analyze serum exosomal miR-216b expression in NSCLC patients and its potential clinical significance.

Methods: A total of 105 NSCLC patients and 60 healthy controls were enrolled, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect serum exosomal miR-216b expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190914DOI Listing
June 2020
1.186 Impact Factor

MARCKS protein overexpression is associated with poor prognosis in male breast cancer.

Cancer Biomark 2019 ;26(4):513-522

Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia.

Background: Male breast cancer (MBC) is a rare and aggressive disease. Thus, identification of new therapeutic targets is crucial.

Objective: Our objective was to evaluate the protein expression of MARCKS (Myristoylated Alanine-Rich C-Kinase Substrate) in MBC and to investigate its prognostic value. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190637DOI Listing
June 2020
5 Reads

Biomarkers Apo10 and TKTL1: Epitope-detection in monocytes (EDIM) as a new diagnostic approach for cholangiocellular, pancreatic and colorectal carcinoma.

Cancer Biomark 2020 ;27(1):129-137

Department of Pediatric Surgery and Pediatric Urology, Children's Hospital, Eberhard-Karls-University Hospital of Tuebingen, Tuebingen, Germany.

Objective: The EDIM (Epitope detection in monocytes) blood test is based on two biomarkers Apo10 and TKTL1. Apo10 is responsible for cell proliferation and resistance to apoptosis. TKTL1 plays a major role in anaerobic glycolysis of tumor cells, leading to destruction of the basal membrane and metastasis as well as in controlling cell cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029314PMC

Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis.

Cancer Biomark 2020 ;27(2):181-188

Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Section of Histology and Medical Embryology, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy.

Background: MicroRNAs (miRNAs) are emerging as promising molecules in the diagnosis, prognosis and treatment of urological tumours. Recently, our group performed two independent studies highlighting that miR-210-3p may be a useful biomarker not only for diagnosis but also for post-surgery clear cell Renal Cell Carcinoma (ccRCC) management.

Objective: The aim of this study is to further explore the effectiveness of miRNA as non-invasive biomarker for clinical outcomes and ccRCC response to the treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190242DOI Listing
January 2020

Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma.

Cancer Biomark 2020 ;27(1):121-128

Advanced Materials Development Laboratory, Sumitomo Chemical Co., Ltd., Osaka, Japan.

Background: Pancreatic ductal adenocarcinoma is a devastating malignancy with an extremely poor prognosis. Although the most widely used biomarker for pancreatic cancer is carbohydrate antigen CA19-9, it is elevated mainly in the late stage of pancreatic cancer. Some serum natural antibodies against carbohydrates have been shown to be possible diagnostic markers for cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190158DOI Listing

FHIT and C-MYC expression in cervical histology and cytology as biomarkers for detecting high-grade intraepithelial neoplasia in human papillomavirus-positive women.

Cancer Biomark 2020 ;27(3):303-312

Background: The current cervical cancer screening strategies based on Papanicolaou (Pap) and Human papillomavirus (HPV) tests receive great achievement but still exhibit many limitations in clinical practice. Exploring new biomarkers as stratified management method in HPV primary screening is becoming the tendency of current research.

Methods: Immunocytochemistry (ICC) of FHIT and C-MYC were performed on exfoliated cervical cells from 197 eligible high-risk HPV positive women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-182232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175930PMC
January 2020

Evaluating prognostic utility of preoperative Neutrophil to Lymphocyte Ratio and hsa-let-7g/c up-regulation in patients with urinary bladder cancer.

Cancer Biomark 2020 ;27(1):63-73

Laboratory of Proteins Engineering and Bioactive Molecules, INSAT, University of Tunis Carthage, Tunis, Tunisia.

Background: Stratification and risk-evaluation of bladder cancer (BCa) patients are far-reached issues, especially for those with non muscle invasive disease. Thus, setting-up biomarkers, especially after resection of the primary tumor, is crucial. Specifically, Neutrophil to lymphocyte ratio NLR and let-7 deregulation which have been preliminarily but not consistently described to be associated to unfavorable prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190483DOI Listing

Differences in cysteine peptidases-like activity in sera of patients with breast cancer.

Cancer Biomark 2020 ;27(3):335-341

Department of Pathophysiology, Wroclaw Medical University, Wroclaw, Poland.

Background: The key role in carcinogenesis with destruction of the extracellular matrix is played by proteases released by invasive cancer cells. Cysteine peptidases, such as cathepsin B and L, take an important role in cancer progression and metastasis.

Objectives: Cysteine peptidase-like activity (CPA) in sera of patients with breast cancer at different stages of disease and the influence of genetic predisposition associated with BRCA-1 gene mutations were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190327DOI Listing
January 2020

Diagnostic value of human epididymis protein 4 in malignant pleural effusion in lung cancer.

Cancer Biomark 2019 ;26(4):523-528

Department of Clinical Laboratory, Nanjing Jiangning Hospital The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Objective: This study aimed to assess the diagnostic value of human epididymis protein 4 (HE4) in the pleural effusion of lung cancer patients.

Methods: HE4 protein in the pleural effusion of 60 lung cancer patients was measured by electrochemiluminescence, in parallel with those from 56 patients with benign lung disease, and the association with malignant pleural effusion was evaluated.

Results: The level of HE4 in samples from lung cancer patients was significantly higher than the level for those with benign lung lesions (P= 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190840DOI Listing
June 2020
9 Reads

Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Cancer Biomark 2019 ;26(4):471-479

Departments of Pathology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Ovarian cancer is the leading cause of death among gynecologic diseases in the USA and Europe. High-grade serous carcinoma (HGSC) of the ovary, the most aggressive type of ovarian cancer, is typically diagnosed at advanced stages when the 5-year survival is dismal. Since the cure rate for stage I HGSC is high, early detection of localized initial disease may improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928436PMC
June 2020
1 Read

Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma.

Cancer Biomark 2020 ;27(1):19-28

Department of Otolaryngology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China.

Purpose: This study endeavors to build a deep learning (DL)-based model for predicting disease progression in head and neck squamous cell carcinoma (HNSCC) patients by integrating multi-omics data.

Methods: RNA sequencing, miRNA sequencing, and methylation data from The Cancer Genome Atlas (TCGA) were used as input for autoencoder, a DL approach. An autoencoder-based prognosis model for PFS was built by SVM algorithm and tested in three confirmation sets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190380DOI Listing

Circulating plasma microRNA signature for the diagnosis of cervical cancer.

Cancer Biomark 2019 ;26(4):491-500

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Objective: To determine the utility of plasma microRNAs (miRNAs) as biomarkers in cervical cancer (CC).

Methods: Some studies were conducted about the specific expression of plasma miRNAs in the diagnosis of CC. Plasma samples of 97 CC patients and 87 normal controls (NCs) were used to identify dysregulation of miRNAs in the training, testing, and external validation phases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190256DOI Listing

Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.

Cancer Biomark 2020 ;27(1):29-37

Background: Tissue biopsy remains the conventional technique for tumor genotyping. The main limitations are it is invasive and provides only partial snapshot during disease progression. Liquid biopsy approaches via plasma and urine are possible alternatives, and the current study aims to provide comparative analyses for plasma and urine derived disease genotyping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-182344DOI Listing

Serum microRNA expression profiling identifies serum biomarkers for HCV-related hepatocellular carcinoma.

Cancer Biomark 2019 ;26(4):501-512

Department of Hepatobiliary Surgery, You'an Hospital Affiliated to Capital Medical University, Beijing, China.

Background: The identification of high-sensitivity biomarkers for detection of hepatocellular carcinoma (HCC) from high-risk individuals is essential.

Objective: The present study was undertaken to identify and validate serum microRNAs (miRNAs) as potential biomarkers for hepatitis C virus (HCV)-related HCC.

Methods: Illumina sequencing was employed to screen the expression profiles of miRNAs in serum samples of HCV-related HCC patients and liver cirrhosis (LC) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-181970DOI Listing
June 2020
1 Read

Identification of hsa_circ_0005654 as a new early biomarker of gastric cancer.

Cancer Biomark 2019 ;26(4):403-410

Gastric cancer is one of the most common cancers in the world. However, current medical technologies have not identified a reliable method to cure advanced gastric cancer, and early gastric cancer is difficult to diagnose. Therefore, we focused on circular RNAs (circRNAs) that have been proven to be involved in the carcinogenesis of gastric cancer. Read More

View Article

Download full-text PDF

Source
https://www.medra.org/servlet/aliasResolver?alias=iospress&a
Publisher Site
http://dx.doi.org/10.3233/CBM-190561DOI Listing
June 2020
1 Read

Bioinformatics analysis of potential prognostic biomarkers among Krüppel-like transcription Factors (KLFs) in breast cancer.

Cancer Biomark 2019 ;26(4):411-420

Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.

Background: Breast cancer is a worldwide leading cause of cancer mortality and it is associated with numerous tumor suppressor genes and oncogenes. Growing evidence exists that different KLFs play pivotal roles of in human malignancies. However, the function of KLFs in breast cancer development has remained uncovered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190199DOI Listing

Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.

Cancer Biomark 2020 ;27(1):11-17

Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Background: Novel biomarkers are needed to predict the effectiveness of the treatment of presurgical neoadjuvant chemotherapy (NAC) in breast cancer (BC).

Objective: This is an exploratory study to assess the impact of 3 cancer-related long non-coding RNAs (lncRNAs) (H19, MALAT1 and GA5) in blood plasma of patients with BC in predicting the response to NAC.

Methods: The plasma levels of RNAs were relatively measured by quantitative PCR at baseline, and at the end of the fourth cycle of NAC in patients with locally advanced BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190085DOI Listing

Relationship between p16 expression and prognosis in different anatomic subsites of OSCC.

Cancer Biomark 2019 ;26(3):375-383

Central Laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing, Jiangsu, China.

Background: p16 has often been found to be overexpressed in patients oral squamous cell carcinoma (OSCC), but its prognostic value between anatomic subsites is still unclear.

Objective: The aim of this study was to investigate the diagnostic and prognostic values of p16 in OSCC originating from tongue, gingiva or buccal mucosa.

Methods: A total of 147 OSCC patients with tumors arising from the tongue, gingiva or buccal mucosa were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-192402DOI Listing
April 2020
2 Reads

Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.

Cancer Biomark 2019 ;26(3):367-373

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.

Background: Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.

Objective: We investigated FAM83A expression in lung adenocarcinoma (LUAD) and its significance in clinicopathologic characteristics and prognosis of the disease.

Patients And Methods: We analyzed the mRNA expression of FAM83A in LUAD and normal (or adjacent) lung tissues from Oncomine database firstly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-190520DOI Listing